Find News

Filter articles

Applied Filters

Showing 131 to 140 of 910 results

Endo pays $2.3m to settle states antitrust claims

US22-07-2019Sarah Morgan

Ireland-headquartered Endo Pharmaceuticals agreed to pay $2.3 million to 18 states late last week, settling allegations that the drugmaker paid a competitor to keep a generic version of pain relief drug Lidoderm off the market.

Johnson & Johnson braces for Q3 sales dip as generics bite

US18-07-2019Saman Javed

Johnson & Johnson has warned that strong competition from generic drugs could impact the company’s figures for the rest of the year.

Delhi court rejects Bayer injunction against Natco Pharma generic

India18-07-2019Saman Javed

India’s Delhi High Court has dismissed a petition for an injunction by German pharma company Bayer against an Indian competitor.

Indivior appeal fails to stop generic opioid addiction challenge

US15-07-2019Saman Javed

The US Court of Appeals for the Federal Circuit has upheld an earlier ruling that Indivior cannot stop two competitors from making a generic version of one of its drugs.

German Court rules Sanofi’s Praluent infringes Amgen patent


A German court has found that Sanofi’s high-cholesterol treatment, Praluent, infringes one of Amgen’s patents.

Reckitt Benckiser to pay $1.4bn over opioid treatment sales

US12-07-2019Sarah Morgan

Reckitt Benckiser has agreed to pay a $1.4 billion fine to settle a US investigation into the sales and marketing of opioid addiction treatment Suboxone film by its former prescriptions business.

Genentech and Samsung Bioepis settle patent dispute over cancer biosimilar


US-based biotechnology company Genentech, a subsidiary of Roche, has entered into a settlement agreement with Samsung Bioepis, ending all patent litigation between the two companies.

UKIPO seeks no-deal Brexit SPC comments

EU, UK05-07-2019

The UK Intellectual Property Office has today, July 5, opened a consultation into supplementary protection certificate law in the event of a ‘no deal’ Brexit.

SPC generics waiver comes into force


The controversial supplementary protection certificate manufacturing waiver has come into force today, July 1.

Novartis secures injunction barring generic MS drugs


A US court has issued an injunction barring the manufacture of generic versions of Swiss pharmaceutical company Novartis’ multiple sclerosis drug Gileyna.

Showing 131 to 140 of 910 results